In vivo anti-cancer efficacy of magnetite nanocrystal - based system using locoregional hyperthermia combined with 5-fluorouracil chemotherapy

Biomaterials

Volumn 34, Issue 32, 2013, Pages 7873-7883

  Li, Tsung Ju ^a   Huang, Chih Chia ^a,b   Ruan, Pin Wei ^a   Chuang, Kuei Yi ^a   Huang, Kuang Jing ^c   Shieh, Dar Bin ^a,c   Yeh, Chen Sheng ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Cancer therapy; Controlled drug release; Hyperthermochemotherapy; Magnetite; Nanomaterials; Radiofrequency

Indexed keywords

5-FLUOROURACIL (5-FU); CANCER THERAPY; CELL VIABILITY ASSAYS; CONTROLLED DRUG RELEASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HYPERTHERMOCHEMOTHERAPY; RADIO FREQUENCIES; RADIO-FREQUENCY ENERGY;

CHEMOTHERAPY; MAGNETITE; NANOSTRUCTURED MATERIALS; NUCLEIC ACIDS; OLIGONUCLEOTIDES; SYNCHRONIZATION; TUMORS;

NANOCRYSTALS;

FLUOROURACIL; MACROGOL; MAGNETITE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HER2; NANOCRYSTAL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER TUMOR; CANCER SURVIVAL; CELL VIABILITY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG RELEASE; HISTOPATHOLOGY; HYPERTHERMIC THERAPY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RADIOFREQUENCY RADIATION; SURVIVAL RATE; TUMOR CELL; TUMOR VOLUME;

EID: 84881026340     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.07.012     Document Type: Article

References (51)

1. Farokhzad O.C., Langer R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Deliver Rev 2006, 58:1456-1459.
2. Park J.H., von Maltzahn G., Ong L.L., Centrone A., Hatton T.A., Ruoslahti E., et al. Cooperative nanoparticles for tumor detection and photothermally triggered drug delivery. Adv Mater 2010, 22:880-885.
3. Li P.C., Wang C.R., Shieh D.B., Wei C.W., Liao C.K., Poe C., et al. Invivo photoacoustic molecular imaging with simultaneous multiple selective targeting using antibody-conjugated gold nanorods. Opt Express 2008, 16:18,605-18,615.
4. Kouloulias V.E., Dardoufas C.E., Kouvaris J.R., Gennatas C.S., Polyzos A.K., Gogas H.J., et al. Liposomal doxorubicin in conjunction with reirradiation and local hyperthermia treatment in recurrent breast cancer: a phase I/II trial. Clin Cancer Res 2002, 8:374-382.
5. Li Q., Li Y.W., Liu Z., Xie R., Shang J.K. Memory antibacterial effect from photoelectron transfer between nanoparticles and visible light photocatalyst. JMater Chem 2010, 20:1068-1072.
6. Davis M.E., Chen Z.G., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7:771-782.
7. Farokhzad O.C., Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009, 3:16-20.
8. Skouras A., Mourtas S., Markoutsa E., De Goltstein M.C., Wallon C., Catoen S., et al. Magnetoliposomes with high USPIO entrapping efficiency, stability and magnetic properties. Nanomedicine 2011, 7:572-579.
9. Mikhaylov G., Mikac U., Magaeva A.A., Itin V.I., Naiden E.P., Psakhye I., et al. Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment. Nat Nano 2011, 6:594-602.
10. 4 nanoparticles and thermosensitive block copolymers. Small 2011, 7:1683-1689.
11. Pradhan P., Giri J., Rieken F., Koch C., Mykhaylyk O., Doblinger M., et al. Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy. JControl Release 2010, 142:108-121.
12. Clemens S., Naumann B., Hippler M. Proteomics of metal mediated protein dynamics in plants - iron and cadmium in the focus. Front Biosci 2009, 14:1955-1969.
13. Kyogoku Y., Lord R.C., Rich A. The effect of substituents on the hydrogen bonding of adenine and uracil derivatives. Proc Natl Acad Sci U S A 1967, 57:250-257.
14. Chandross R., Rich A. The crystal structure of the 2:1 intermolecular complex containing 1-melhyl-5-flourouracil and 9-ethyl-2,6-diaminopurine. Biopolymers 1971, 10:1795-1807.
15. Hergt R., Dutz S. Magnetic particle hyperthermia - biophysical limitations of a visionary tumour therapy. JMagn Magn Mater 2007, 311:187-192.
16. Lin C.-C., Chou C.-W., Shiau A.-L., Tu C.-F., Ko T.-M., Chen Y.-L., et al. Therapeutic HER2/neu DNA vaccine inhibits mouse tumor naturally overexpressing endogenous neu. Mol Ther 2004, 10:290-301.
17. Gorczyca W., Gong J., Darzynkiewicz Z. Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer Res 1993, 53:1945-1951.
18. Katschinski D.M., Robins H.I., Schad M., Frede S., Fandrey J. Role of tumor necrosis factor alpha in hyperthermia-induced apoptosis of human leukemia cells. Cancer Res 1999, 59:3404-3410.
19. Huang C.-C., Tsai C.-Y., Sheu H.-S., Chuang K.-Y., Su C.-H., Jeng U.S., et al. Enhancing transversal relaxation for magnetite nanoparticles in MR imaging using Gd3+-chelated mesoporous silica shells. ACS nano 2011, 5:3905-3916.
20. Grivicich I., Regner A., Zanoni C., Correa L.P., Jotz G.P., Henriques J.A., et al. Hsp70 response to 5-fluorouracil treatment in human colon cancer cell lines. Int J Colorectal Dis 2007, 22:1201-1208.
21. Decatris M.P., Sundar S., O'Byrne K.J. Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer Treat Rev 2004, 30:53-81.
22. Zhao L., Chen Z., Wang J., Yang L., Zhao Q., Wang J., et al. Synergistic effect of 5-fluorouracil and the flavanoid oroxylin A on HepG2 human hepatocellular carcinoma and on H22 transplanted mice. Cancer Chemoth Pharm 2010, 65:481-489.
23. Rich T.A., Shepard R.C., Mosley S.T. Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. JClin Oncol 2004, 22:2214-2232.
24. Han R., Yang Y.M., Dietrich J., Luebke A., Mayer-Proschel M., Noble M. Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. Jbio 2008, 7:12.
25. Ezzeldin H., Diasio R. Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin Colorectal canc 2004, 4:181-189.
26. Ng M., Cunningham D., Norman A.R. The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). Eur J Cancer 2005, 41:1542-1546.
27. van Groeningen C.J., Peters G.J., Pinedo H.M. Reversal of 5-fluorouracil-induced toxicity by oral administration of uridine. Ann oncol 1993, 4:317-320.
28. Wong H.L., Bendayan R., Rauth A.M., Li Y., Wu X.Y. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliver Rev 2007, 59:491-504.
29. Durán J.D.G., Arias J.L., Gallardo V., Delgado A.V. Magnetic colloids as drug vehicles. JPharm Sci 2008, 97:2948-2983.
30. Zhang N., Yin Y., Xu S.J., Chen W.S. 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules 2008, 13:1551-1569.
31. Arias J.L., Ruiz M.A., López-Viota M., Delgado Á.V. Poly(alkylcyanoacrylate) colloidal particles as vehicles for antitumour drug delivery: a comparative study. Colloid Surf B-Biointerfaces 2008, 62:64-70.
32. Crayton S.H., Tsourkas A. pH-titratable superparamagnetic iron oxide for improved nanoparticle accumulation in acidic tumor microenvironments. ACS Nano 2011, 5:9592-9601.
33. Chou S.W., Shau Y.H., Wu P.C., Yang Y.S., Shieh D.B., Chen C.C. Invitro and invivo studies of FePt nanoparticles for dual modal CT/MRI molecular imaging. JAm Chem Soc 2010, 132:13,270-13,278.
34. Li P.C., Wei C.W., Liao C.K., Chen C.D., Pao K.C., Wang C.R., et al. Photoacoustic imaging of multiple targets using gold nanorods. IEEE T Ultrason Ferr 2007, 54:1642-1647.
35. Lartigue L., Innocenti C., Kalaivani T., Awwad A., Duque MdM Sanchez, Guari Y., et al. Water-dispersible sugar-coated iron oxide nanoparticles. An evaluation of their relaxometric and magnetic hyperthermia properties. JAm Chem Soc 2011, 133:10,459-10,472.
36. Lee J.H., Jang J.T., Choi J.S., Moon S.H., Noh S.H., Kim J.W., et al. Exchange-coupled magnetic nanoparticles for efficient heat induction. Nat Nano 2011, 6:418-422.
37. Gonzales-Weimuller M., Zeisberger M., Krishnan K.M. Size-dependant heating rates of iron oxide nanoparticles for magnetic fluid hyperthermia. JMagn Magn Mater 2009, 321:1947-1950.
38. Shiau A.L., Lin Y.P., Shieh G.S., Su C.H., Wu W.L., Tsai Y.S., et al. Development of a conditionally replicating pseudorabies virus for HER-2/neu-overexpressing bladder cancer therapy. Mol Ther 2007, 15:131-138.
39. Gormley A.J., Larson N., Sadekar S., Robinson R., Ray A., Ghandehari H. Guided delivery of polymer therapeutics using plasmonic photothermal therapy. Nano Today 2012, 7:158-167.
40. Roviello F., Caruso S., Marrelli D., Pedrazzani C., Neri A., De Stefano A., et al. Treatment of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: state of the art and future developments. Surg Oncol 2011, 20:e38-e54.
41. Ciofani G., Riggio C., Raffa V., Menciassi A., Cuschieri A. Abi-modal approach against cancer: magnetic alginate nanoparticles for combined chemotherapy and hyperthermia. Med Hypotheses 2009, 73:80-82.
42. Sherlock S.P., Tabakman S.M., Xie L., Dai H. Photothermally enhanced drug delivery by ultrasmall multifunctional FeCo/Graphitic shell nanocrystals. ACS Nano 2011, 5:1505-1512.
43. Gormley A.J., Greish K., Ray A., Robinson R., Gustafson J.A., Ghandehari H. Gold nanorod mediated plasmonic photothermal therapy: a tool to enhance macromolecular delivery. Int J Pharm 2011, 415:315-318.
44. Johannsen M., Gneveckow U., Eckelt L., Feussner A., Waldofner N., Scholz R., et al. Clinical hyperthermia of prostate cancer using magnetic nanoparticles: presentation of a new interstitial technique. Int J Hyperther 2005, 21:637-647.
45. Lee C.K., Song C.W., Rhee J.G., Foy J.A., Levitt S.H. Clinical experience using 8MHz radiofrequency capacitive hyperthermia in combination with radiotherapy: results of a phase III study. Int J Radiat Oncol 1995, 32:733-745.
46. Adair E.R., Blick D.W., Allen S.J., Mylacraine K.S., Ziriax J.M., Scholl D.M. Thermophysiological responses of human volunteers to whole body RF exposure at 220MHz. Bioelectromagnetics 2005, 26:448-461.
47. Ito A., Matsuoka F., Honda H., Kobayashi T. Heat shock protein 70 gene therapy combined with hyperthermia using magnetic nanoparticles. Cancer Gene Ther 2003, 10:918-925.
48. Sanson C., Diou O., Thevenot J., Ibarboure E., Soum A., Brulet A., et al. Doxorubicin loaded magnetic polymersomes: theranostic nanocarriers for MR imaging and magneto-chemotherapy. ACS Nano 2011, 5:1122-1140.
49. Hong H., Yang K., Zhang Y., Engle J.W., Feng L., Yang Y., et al. Invivo targeting and imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographene. ACS Nano 2012, 6:2361-2370.
50. Rosen J.E., Chan L., Shieh D.B., Gu F.X. Iron oxide nanoparticles for targeted cancer imaging and diagnostics. Nanomedicine 2012, 8:275-290.
51. 4 nanoparticles: high magnetization magnetites as effective hepatic contrast agents. JMater Chem 2011, 21:7472-7479.